View Exam | PowerPak

1. Which of the following is/are appropriate indications for insulin replacement therapy?

A. An individual in hyperglycemic crisis (e.g., diabetic ketoacidosis) B. A person with an A1C >9.0% who is symptomatic C. A hospitalized individual receiving enteral nutrition D. All of the above

2. According to the American Diabetes Association (ADA) recommendations for antihyperglycemic therapy in type 2 diabetes, which of the following is a true benefit of using basal insulin as a second line add-on therapy to background metformin when compared to other drug classes?

A. The addition of basal insulin has the highest level of efficacy B. The addition of basal insulin has the lowest risk of hypoglycemia C. The addition of basal insulin has a neutral effect on weight D. None of the above

3. Which of the following is NOT a key patient barrier to insulin therapy?

A. Fear of injections B. Fear of weight gain C. Fear of hyperglycemia D. Fear of a loss of independence

4. Which of the following basal insulin products is considered an “Ultra-long” basal insulin?

A. U-300 insulin glargine B. U-100 insulin glargine C. Insulin detemir D. NPH insulin

5. Which of the following statements is FALSE regarding the concentrated insulin products U-300 insulin glargine and U-200 insulin degludec?

A. These concentrated insulins are only available in prefilled pens to minimize the risk of dosing errors B. Due to their longer duration of action, these concentrated insulins are associated with higher rates of hypoglycemia when compared to U-100 insulin glargine C. These concentrated insulin products allow for a smaller volume of insulin injection when compared to U-100 insulin products D. When administering a dose of insulin with concentrated insulins, the dose is simply dialed on the insulin pen (e.g., no dose conversion needed)

6. According to the prescribing information for U-300 insulin glargine, if a patient is currently taking 10 units of U-100 insulin glargine once daily, what would be the recommended starting dose if she is switched to U-300 insulin glargine?

A. 8 units of U-300 insulin glargine B. 10 units of U-300 insulin glargine C. 12 units of U-300 insulin glargine D. 11 units of U-300 insulin glargine

7. Which of the following basal insulins is formulated in an acidic solution and when injected forms microprecipitates in the subcutaneous tissue that allows for delayed absorption and a protracted duration of action?

A. Insulin detemir B. Insulin degludec C. Insulin glargine D. Insulin glulisine

8. RS is a 65 year old man with type 2 diabetes. He weighs 100 kg. Based on the American Diabetes Association (ADA) recommendations for the initiation of basal insulin, which of the following options would be an appropriate starting dose of basal insulin?

A. 10 units per day B. 5 units per day C. 20 units per day D. Both A and C would be appropriate options

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is/are appropriate indications for insulin replacement therapy?

2. According to the American Diabetes Association (ADA) recommendations for antihyperglycemic therapy in type 2 diabetes, which of the following is a true benefit of using basal insulin as a second line add-on therapy to background metformin when compared to other drug classes?

3. Which of the following is NOT a key patient barrier to insulin therapy?

4. Which of the following basal insulin products is considered an “Ultra-long” basal insulin?

5. Which of the following statements is FALSE regarding the concentrated insulin products U-300 insulin glargine and U-200 insulin degludec?

6. According to the prescribing information for U-300 insulin glargine, if a patient is currently taking 10 units of U-100 insulin glargine once daily, what would be the recommended starting dose if she is switched to U-300 insulin glargine?

7. Which of the following basal insulins is formulated in an acidic solution and when injected forms microprecipitates in the subcutaneous tissue that allows for delayed absorption and a protracted duration of action?

8. RS is a 65 year old man with type 2 diabetes. He weighs 100 kg. Based on the American Diabetes Association (ADA) recommendations for the initiation of basal insulin, which of the following options would be an appropriate starting dose of basal insulin?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is/are appropriate indications for insulin replacement therapy?

2. According to the American Diabetes Association (ADA) recommendations for antihyperglycemic therapy in type 2 diabetes, which of the following is a true benefit of using basal insulin as a second line add-on therapy to background metformin when compared to other drug classes?

3. Which of the following is NOT a key patient barrier to insulin therapy?

4. Which of the following basal insulin products is considered an “Ultra-long” basal insulin?

5. Which of the following statements is FALSE regarding the concentrated insulin products U-300 insulin glargine and U-200 insulin degludec?

6. According to the prescribing information for U-300 insulin glargine, if a patient is currently taking 10 units of U-100 insulin glargine once daily, what would be the recommended starting dose if she is switched to U-300 insulin glargine?

7. Which of the following basal insulins is formulated in an acidic solution and when injected forms microprecipitates in the subcutaneous tissue that allows for delayed absorption and a protracted duration of action?

8. RS is a 65 year old man with type 2 diabetes. He weighs 100 kg. Based on the American Diabetes Association (ADA) recommendations for the initiation of basal insulin, which of the following options would be an appropriate starting dose of basal insulin?

« Return to Activity

Customers who Purchased
this Activity also Purchased